Header Ads

πŸ“ˆπŸ“ˆ Bullish Penny Stocks $1-$10 for 7.2.2019 πŸ’΅πŸ’΅ - #stockstowatch #pennystocks

What Is a Penny Stock: A penny stock refers to a small company's stock that typically trades for less than $5 per share. Although some penny stocks trade on large exchanges such as the New York Stock Exchange (NYSE), mostpenny stocks trade via over the counter (OTC) transactions. Transactions take place through the electronic OTC Bulletin Board (OTCBB) or through the privately-owned Pink Sheets. There is no trading floor for OTC transactions, and the quotations are also all done electronically.


Jonny Red's Penny Stock Trade Thoughts Below:

The below listed Penny Stock Tickers are all those that meet the criteria of the scanner.  These are tickers that need to be watched and analyzed at Market Open to see if they will continue their Northern Momentum. I have posted a few of the charts for my favorite ones.

All of these tickers close today with 3 consecutive Green closes. I typically always look for penny's stock plays that have 2 to 3 consecutive GREEN days, and at least 800k+ in volume.

Transparent Trader Bullish Penny Stocks $1-$10 Range: http://tos.mx/izmLDK

Transparent Traders Low Float Scanner for Penny Stocks http://tos.mx/OKvQSM

See all Bullish Tickers below, but My Top 3 Ticker Symbols are: ENDP - KDMN - GNC


ENDP - Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. Its U.S. Branded - Specialty & Established Pharmaceuticals segment provides branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain, and orthopedics. This segment offers XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL Nasal Spray to treat vitamin B12 deficiency; TESTOPEL for TRT in conditions associated with a deficiency or absence of endogenous testosterone; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; VOLTAREN Gel for the relief of joint pain of osteoarthritis; LIDODERM for the relief of pain; FORTESTA Gel for men suffering from hypogonadism; EDEX to treat erectile dysfunction; and TESTIM for TRT in conditions associated with a deficiency or absence of endogenous testosterone. The company's U.S. Branded - Sterile Injectables segment offers branded sterile injectable products, such as VASOSTRICT, ADRENALIN, and APLISOL; and generic sterile injectable products. Its U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics, and sprays; and products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. The company was founded in 1920 and is headquartered in Dublin, Ireland.


KDMN - Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; KD045, an ROCK inhibitor for the treatment of fibrotic diseases; KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Zydus Pharmaceuticals USA, Inc.; and Jinghua Pharmaceutical Group Co., Ltd. The company is headquartered in New York, New York.


GNC - GNC Holdings, Inc., together with its subsidiaries, operates as a specialty retailer of health, wellness, and performance products. The company operates through three segments: U.S. and Canada, International, and Manufacturing/Wholesale. Its products include proteins, performance supplements, weight management supplements, vitamins, herbs and greens, wellness supplements, health and beauty products, food and drink products, and other general merchandise. The company also provides third-party contract manufacturing services. It sells its products under the GNC proprietary brands, as well as under third-party brands. As of December 31, 2018, the company had approximately 8,400 locations of which approximately 6,200 retail locations in the United States and franchise operations in approximately 50 countries. It sells its products through company-owned retail stores and its Website GNC.com, as well as third-party Websites; wholesale partnerships; and domestic and internatio
nal franchise activities. GNC Holdings, Inc. has a strategic partnership with Harbin Pharmaceutical Group Holding Co., Ltd. and International Vitamin Corporation. The company was founded in 1935 and is headquartered in Pittsburgh, Pennsylvania.



πŸ’₯ Finding FDA Catalyst for Stocks πŸ“ˆ | Stock Market



No comments